Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1968 1
1969 2
1970 1
1971 3
1972 3
1973 1
1975 1
1976 1
1977 1
1978 1
1979 1
1980 4
1981 2
1982 3
1983 5
1984 7
1985 5
1986 8
1987 8
1988 11
1989 6
1990 14
1991 16
1992 7
1993 16
1994 24
1995 41
1996 35
1997 38
1998 35
1999 49
2000 54
2001 43
2002 47
2003 49
2004 61
2005 62
2006 64
2007 46
2008 55
2009 51
2010 39
2011 41
2012 39
2013 43
2014 43
2015 44
2016 41
2017 35
2018 33
2019 26
2020 22
2021 24
2022 18
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

1,205 results
Results by year
Filters applied: . Clear all
Page 1
Dehydroepiandrosterone Shifts Energy Metabolism to Increase Mitochondrial Biogenesis in Female Fertility with Advancing Age.
Li CJ, Lin LT, Tsui KH. Li CJ, et al. Nutrients. 2021 Jul 17;13(7):2449. doi: 10.3390/nu13072449. Nutrients. 2021. PMID: 34371958 Free PMC article. Clinical Trial.
Female reproductive aging is an irreversible process associated with a decrease in oocyte quality, which is a limiting factor for fertility. Previous studies have shown that dehydroepiandrosterone (DHEA) has been shown to improve in vitro fertilization (IVF) outcomes in ol …
Female reproductive aging is an irreversible process associated with a decrease in oocyte quality, which is a limiting factor for fertility. …
Effect of dehydroepiandrosterone administration before in vitro fertilization on the live birth rate in poor ovarian responders according to the Bologna criteria: A randomised controlled trial.
Wang Z, Yang A, Bao H, Wang A, Deng X, Xue D, Tan H, Zhou Y, Wu C, Chen ZJ, Shi Y. Wang Z, et al. BJOG. 2022 Jun;129(7):1030-1038. doi: 10.1111/1471-0528.17045. Epub 2021 Dec 29. BJOG. 2022. PMID: 34882964 Clinical Trial.
OBJECTIVE: To evaluate the effect of dehydroepiandrosterone (DHEA) pre-treatment before in vitro fertilization and embryo transfer (IVF-ET) on the live birth rate in infertile women with poor ovarian response (POR) defined according to the Bologna criteria. ...
OBJECTIVE: To evaluate the effect of dehydroepiandrosterone (DHEA) pre-treatment before in vitro fertilization and embryo transfer (I …
Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus.
Petri MA, Mease PJ, Merrill JT, Lahita RG, Iannini MJ, Yocum DE, Ginzler EM, Katz RS, Gluck OS, Genovese MC, Van Vollenhoven R, Kalunian KC, Manzi S, Greenwald MW, Buyon JP, Olsen NJ, Schiff MH, Kavanaugh AF, Caldwell JR, Ramsey-Goldman R, St Clair EW, Goldman AL, Egan RM, Polisson RP, Moder KG, Rothfield NF, Spencer RT, Hobbs K, Fessler BJ, Calabrese LH, Moreland LW, Cohen SB, Quarles BJ, Strand V, Gurwith M, Schwartz KE. Petri MA, et al. Arthritis Rheum. 2004 Sep;50(9):2858-68. doi: 10.1002/art.20427. Arthritis Rheum. 2004. PMID: 15452837 Free article. Clinical Trial.
OBJECTIVE: To determine whether prasterone administration results in improvement or stabilization of systemic lupus erythematosus (SLE) disease activity and its symptoms. ...Acne and hirsutism were reported in 33% and 16%, respectively, of the prasterone group and i …
OBJECTIVE: To determine whether prasterone administration results in improvement or stabilization of systemic lupus erythematosus (SL …
Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy.
Sánchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Wallace DJ, Ginzler EM, Sherrer YR, McIlwain HH, Freeman PG, Aranow C, Petri MA, Deodhar AA, Blanton E, Manzi S, Kavanaugh A, Lisse JR, Ramsey-Goldman R, McKay JD, Kivitz AJ, Mease PJ, Winkler AE, Kahl LE, Lee AH, Furie RA, Strand CV, Lou L, Ahmed M, Quarles B, Schwartz KE. Sánchez-Guerrero J, et al. J Rheumatol. 2008 Aug;35(8):1567-75. Epub 2008 Jul 15. J Rheumatol. 2008. PMID: 18634158 Clinical Trial.
METHODS: 155 patients with SLE received 200 mg/day prasterone or placebo for 6 months in a double-blind phase. Subsequently, 114 patients were re-randomized to receive 200 or 100 mg/day prasterone for 12 months in an open-label phase. ...There was no overall change …
METHODS: 155 patients with SLE received 200 mg/day prasterone or placebo for 6 months in a double-blind phase. Subsequently, 114 pati …
Combined data of intravaginal prasterone against vulvovaginal atrophy of menopause.
Labrie F, Archer DF, Martel C, Vaillancourt M, Montesino M. Labrie F, et al. Menopause. 2017 Nov;24(11):1246-1256. doi: 10.1097/GME.0000000000000910. Menopause. 2017. PMID: 28640161 Clinical Trial.
OBJECTIVE: To analyze the effects of intravaginal prasterone obtained in the three randomized clinical studies performed in postmenopausal women suffering from moderate to severe (MS) dyspareunia due to vulvovaginal atrophy (VVA). ...RESULTS: In 436 women treated with 0.50 …
OBJECTIVE: To analyze the effects of intravaginal prasterone obtained in the three randomized clinical studies performed in postmenop …
Intravaginal dehydroepiandrosterone (Prasterone), a physiological and highly efficient treatment of vaginal atrophy.
Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Labrie F, et al. Menopause. 2009 Sep-Oct;16(5):907-22. doi: 10.1097/gme.0b013e31819e8e2d. Menopause. 2009. PMID: 19436225 Clinical Trial.
OBJECTIVE: Because the secretion of dehydroepiandrosterone (DHEA), the exclusive source of sex steroids in postmenopausal women, is already decreased by 60% and continues to decline at the time of menopause, the objective of this study was to examine the effect of intravag …
OBJECTIVE: Because the secretion of dehydroepiandrosterone (DHEA), the exclusive source of sex steroids in postmenopausal women, is a …
Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia.
Labrie F, Archer DF, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Labrie F, et al. Climacteric. 2011 Apr;14(2):282-8. doi: 10.3109/13697137.2010.535226. Epub 2011 Jan 18. Climacteric. 2011. PMID: 21244215 Clinical Trial.
OBJECTIVE: To examine the effect of intravaginal dehydroepiandrosterone (DHEA) on pain at sexual activity (dyspareunia) identified as the most bothersome symptom of vaginal atrophy in postmenopausal women at both screening and day 1. METHODS: This prospective, randomized, …
OBJECTIVE: To examine the effect of intravaginal dehydroepiandrosterone (DHEA) on pain at sexual activity (dyspareunia) identified as …
Effect of intravaginal dehydroepiandrosterone (Prasterone) on libido and sexual dysfunction in postmenopausal women.
Labrie F, Archer D, Bouchard C, Fortier M, Cusan L, Gomez JL, Girard G, Baron M, Ayotte N, Moreau M, Dubé R, Côté I, Labrie C, Lavoie L, Berger L, Gilbert L, Martel C, Balser J. Labrie F, et al. Menopause. 2009 Sep-Oct;16(5):923-31. doi: 10.1097/gme.0b013e31819e85c6. Menopause. 2009. PMID: 19424093 Clinical Trial.
METHODS: This prospective, randomized, double-blind, and placebo-controlled phase III clinical trial has evaluated the effect of daily local intravaginal application of Prasterone (dehydroepiandrosterone; DHEA) for 12 weeks on the domains of sexual dysfunction, name …
METHODS: This prospective, randomized, double-blind, and placebo-controlled phase III clinical trial has evaluated the effect of daily local …
Treatment of pain at sexual activity (dyspareunia) with intravaginal dehydroepiandrosterone (prasterone).
Archer DF, Labrie F, Bouchard C, Portman DJ, Koltun W, Cusan L, Labrie C, Côté I, Lavoie L, Martel C, Balser J; VVA Prasterone Group. Archer DF, et al. Menopause. 2015 Sep;22(9):950-63. doi: 10.1097/GME.0000000000000428. Menopause. 2015. PMID: 25734980 Clinical Trial.
OBJECTIVE: This study aims to confirm the local effects of intravaginal prasterone on moderate to severe dyspareunia, a symptom of vulvovaginal atrophy (VVA) associated with menopause. ...No significant drug-related adverse effect in line with the strictly local action of …
OBJECTIVE: This study aims to confirm the local effects of intravaginal prasterone on moderate to severe dyspareunia, a symptom of vu …
Evaluation of the acceptability of intravaginal prasterone ovule administration using an applicator.
Montesino M, Labrie F, Archer DF, Zerhouni J, Côté I, Lavoie L, Beauregard A, Martel C, Vaillancourt M, Moyneur E, Balser J. Montesino M, et al. Gynecol Endocrinol. 2016;32(3):240-5. doi: 10.3109/09513590.2015.1110140. Epub 2016 Jan 6. Gynecol Endocrinol. 2016. PMID: 26634942 Clinical Trial.
The objective of the study is to evaluate the acceptability of the intravaginal administration of ovules/suppositories of DHEA (dehydroepiandrosterone, prasterone) for the treatment of vulvovaginal atrophy (VVA) in women with moderate to severe dyspareunia who were …
The objective of the study is to evaluate the acceptability of the intravaginal administration of ovules/suppositories of DHEA (dehydroep …
1,205 results